Tuesday, January 27, 2015 2:06:26 PM
In turning down the request to cut short the usual twenty-five-day period for formal implementation of a decision, Justice Breyer did so “without prejudice.” Under the Court’s Rule 22, when that is the form of a denial of an application to an individual member of the Court, a new application may be submitted to a different Justice. That left it up to the generic companies to try again. If they do, it is up to them to choose the Justice to whom they want to submit the renewed application.
The generic companies are hoping to get permission soon from the Food and Drug Administration to put their own version of Copaxone, a very profitable drug used mainly to treat multiple sclerosis patients, on the market. Teva’s current patent on that brand-name drug is due to expire on September 1.
The Teva case is due to return to the U.S. Court of Appeals for the Federal Circuit, to take another look at the validity of Teva’s remaining patent. Earlier, the Federal Circuit found the patent invalid, but the Supreme Court overturned that result last week, without deciding whether the patent is or is not valid. It ordered the Federal Circuit to reconsider, using a different review standard.
The generics want the normal time period for releasing a new ruling shortened so that the new proceedings at the Federal Circuit can proceed promptly. Teva wants to be able to ensure that its patent monopoly remains intact while those proceedings continue. It has said it will be asking a federal trial judge in New York City to ensure that that happens.
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM